KPV (oral)

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, Lys-Pro-Val (residues 11–13), approximately 325 daltons. Fragmentation studies of alpha-MSH localised the anti-inflammatory activity to this sequence, first described by Hiltz and Lipton (1989).

Unlike the parent hormone and unlike MT-1 or MT-2, KPV does not bind melanocortin receptors. It carries the anti-inflammatory and antimicrobial properties of alpha-MSH with no effect on pigmentation, appetite, or sexual function. Its mechanism runs through intracellular uptake via the PepT1 di/tripeptide transporter rather than surface receptor signalling.

The small molecular size permits oral, subcutaneous, and topical administration. This entry covers the oral route, available as capsule, solution, or a 500 mcg buccal pill held between gum and cheek until dissolved, with a 15-minute abstention from food and drink afterwards. Buccal absorption is systemic and bypasses gastric proteolysis and hepatic first pass; a swallowed capsule reaches the intestinal lumen directly, which is where PepT1-mediated uptake into inflamed epithelium occurs. The two oral presentations therefore differ in exposure pattern.

As of early 2026 the entire evidence base is preclinical: cell culture and animal models, principally DSS- and TNBS-induced colitis in mice. No human clinical trials or dose-finding studies exist for any route.

KPV's primary action is suppression of NF-kB activation, reducing downstream transcription of pro-inflammatory cytokines including TNF-alpha, IL-1 beta, IL-6, and IL-8. It additionally inhibits MAP kinase signalling, a parallel cascade that amplifies the inflammatory response. Dual pathway inhibition produces a broad anti-inflammatory effect at nanomolar concentrations (Dalmasso et al., 2008).

The mechanism is receptor-independent. KPV enters cells through PepT1, the H+-coupled di/tripeptide transporter expressed on intestinal epithelium and on immune cells, and interferes with NF-kB and MAP kinase signalling from the cytosol. In the 2016 colitis-associated cancer model the anti-tumour effect was absent in PepT1 knockout mice, confirming transporter dependence.

PepT1 expression is upregulated in colonic tissue during inflammatory bowel disease, so inflamed mucosa presents more transporters and takes up proportionally more KPV. This self-targeting property is the rationale for oral delivery in gut inflammation: the same transporter that absorbs dietary tripeptides delivers KPV to the affected epithelial cells.

KPV modulates rather than suppresses immunity. Unlike corticosteroids it does not produce global immunosuppression; Cutuli et al. (2000) showed it enhances neutrophil killing of pathogens, with direct antimicrobial activity mediated through increased cellular cAMP.

In DSS- and TNBS-induced murine colitis, oral KPV reduced colitis severity, decreased colonic pro-inflammatory cytokine expression, and preserved barrier integrity; in one study treatment rescued all animals from death during severe DSS colitis. Xiao et al. (2017) showed hyaluronic acid-functionalised nanoparticles loaded with KPV targeted inflamed colitis tissue and outperformed free KPV on mucosal healing and inflammation.

Anti-inflammatory activity extends to animal models of contact dermatitis, arthritis, colitis, and allergic asthma. Brzoska et al. (2008) described KPV as exerting similar or even more pronounced anti-inflammatory activity than full-length alpha-MSH. Topically it reduces inflammation and accelerates wound closure without the epidermal thinning or immunosuppression of corticosteroids, and without pigmentary change.

Antimicrobial activity against *S. aureus* and *C. albicans* was demonstrated at concentrations as low as picomolar, with enhanced rather than reduced neutrophil pathogen killing (Cutuli et al., 2000). Hiltz and Lipton (1989) reported antipyretic activity.

Earlier site material additionally lists immune stimulation, recovery from liver injury via increased hepatocyte replication, reduced scarring with improved collagen fibre organisation, and prolonged graft survival.

Dalmasso et al. (2016) found PepT1-mediated KPV delivery prevented carcinogenesis in a colitis-associated cancer model. A 2025 systematic review in JGH Open identified KPV among the most promising anti-inflammatory peptides for IBD while stressing the absence of human trials.

With no human clinical data, expectations rest on preclinical models and anecdotal reports and should be weighted accordingly.

In murine colitis, measurable reductions in intestinal inflammatory markers appeared within days of oral KPV; mucosal healing and barrier restoration followed over subsequent weeks.

Users report reduced bloating and improved digestion within 2 to 4 weeks of oral use, with more substantial improvement in inflammatory symptoms at 4 to 8 weeks of consistent dosing. Outcomes in suspected IBD or chronic intestinal disease are more variable, with some reporting meaningful improvement and others little change.

KPV is a daily modulator, not an acute rescue agent; effect accrues through sustained reduction of inflammatory signalling.

Tolerability is consistently described as exceptionally good. Occasional gastrointestinal upset at higher oral doses is the route-specific report. Preclinical studies note low toxicity and a favourable safety profile, but long-term human safety is unknown. Inflammatory markers (CRP, ESR) and symptom tracking are reasonable monitoring points for gut-related use.

No reconstitution. Presentations: capsule, solution, or 500 mcg buccal pill.

Standard oral protocol: 200 to 500 mcg once or twice daily for 4 to 8 weeks, extendable with monitoring. Use case: gut inflammation, intestinal permeability, IBD support. Oral delivery is supported by the PepT1 mechanism. Earlier site material gives a 2–4 week washout between cycles.

500 mcg buccal pill. Held between gum and cheek until dissolved; 15-minute abstention from food and drink after dissolution. Best fasted, 1.5–2 hours either side of a meal. Options: 500 mcg once daily on waking, or 1,000 mcg daily as 500 mcg on waking plus 500 mcg in the afternoon or evening. The second doubles daily exposure rather than splitting it. Buccal absorption is systemic and bypasses gastric proteolysis and first pass; a swallowed capsule instead delivers to the lumen where inflamed epithelium expresses upregulated PepT1. The two presentations therefore have different exposure profiles, and no bioavailability figure exists for either.

Route selection. Oral is the logical route for gut-specific indications. For systemic anti-inflammatory effect or skin conditions the subcutaneous route (200 to 400 mcg once daily) offers better systemic bioavailability; topical 0.01 to 0.1% cream is used for skin.

No human dose-finding studies exist for any route. The protocol reflects clinical practice patterns, not trial data. Occasional gastrointestinal upset is reported at higher oral doses.

The evidence base is entirely preclinical as of early 2026: cell culture and animal models, predominantly murine colitis. No human clinical trials and no human dose-finding studies by any route have been published. The oral protocol is a practice-pattern figure, not a trial-derived one.

Dalmasso et al. (2008), Gastroenterology, is the landmark mechanism paper. Nanomolar KPV inhibited NF-kB and MAP kinase activation and reduced pro-inflammatory cytokine secretion (TNF-alpha, IL-1 beta, IL-6, IL-8). Uptake was PepT1-mediated with no melanocortin receptor involvement. Oral KPV reduced colitis severity in DSS and TNBS models and decreased colonic cytokine expression. PepT1 is upregulated in inflamed colon, giving oral dosing a self-targeting quality directly relevant to this presentation.

Dalmasso et al. (2016), Cellular and Molecular Gastroenterology and Hepatology: PepT1-mediated KPV delivery prevented carcinogenesis in a colitis-associated cancer model; the effect was absent in PepT1 knockout mice. Xiao et al. (2017), Molecular Therapy: hyaluronic acid-functionalised nanoparticles loaded with KPV targeted inflamed colitis tissue and outperformed free KPV on mucosal healing and inflammation.

Hiltz and Lipton (1989), FASEB Journal, established KPV as the active anti-inflammatory C-terminal sequence of alpha-MSH and demonstrated anti-pyretic effects. Brzoska et al. (2008), Endocrine Reviews, concluded KPV exerts "similar or even more pronounced anti-inflammatory activity" than full-length alpha-MSH across contact dermatitis, arthritis, colitis, and asthma models, with low toxicity. Cutuli et al. (2000): direct antimicrobial activity against S. aureus and C. albicans at picomolar concentrations, mediated via increased cellular cAMP, with enhanced rather than reduced neutrophil pathogen killing.

A 2025 systematic review in JGH Open ranked KPV among the most promising anti-inflammatory peptides for IBD on preclinical evidence and emphasised the critical need for human trials.

Interpretation: mechanism and murine efficacy are well characterised and coherent for enteric inflammation; human translation is unproven, and no bioavailability figure exists for any oral or buccal presentation.